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A bottom-up approach was applied to analyze the cost
and revenue situation from a hospital outpatient clinics
and a resident oncologists perspective.
The treatment process for the intravenous and
subcutaneous administration was analyzed by using
cost and accounting data from ten health care
providers (e.g. labour costs, lease costs, TARMED
tariff numbers applied), information from official tariff
systems (e.g. prices of drugs, medical devices and
consumables) and literature. Based on this data four
calculation models showing costs and revenues were
established for each drug and type of health care
provider setting. These calculation models were
established for single administrations in both treatment
phases (induction and maintenance phase) as well as
for the entire therapy.
In a sensitivity analysis four scenarios were scrutinized,
among others a 20% price reduction and a 10%
discount on the drug prices of the subcutaneous
application.
Methods
For resident oncologists the change results in a lower
profit margin of CHF 2'833 per entire Herceptin therapy
and CHF 3'044 per entire MabThera therapy (Figure 1).
Figure 1: Profit margin for resident oncologists
For hospital outpatient clinics the change results in a
lower profit margin of CHF 2‘139 per entire Herceptin
therapy and CHF 2’862 per entire MabThera therapy
(Figure 2).
Figure 2: Profit margin for hospital outpatient clinics
The sensitivity analysis showed that a price reduction
of 20% and a 10% discount on drug prices of the
subcutaneous application reduces the loss of profit
margin to CHF 550 or could even lead to a profit of
CHF 140 per entire therapy depending on the setting.
Results
In Switzerland, every year about 5’500 women are
diagnosed with breast cancer and 1’500 people with
non-Hodgkin's lymphoma [1]. The targeted therapy
with MabThera® is the standard of care for many
patients with Non-Hodgkin’s lymphoma, whereas
Herceptin® is approved for the treatment of a certain
type of breast cancer. Currently both drugs are
administered intravenously (IV), yet a subcutaneous
application (SC) is in development.
Assuming the same price for the future subcutaneous
formulation, this study compared the cost and revenue
situation of both application forms. The analysis was
performed both in hospital outpatient- and resident
oncologists-settings in Switzerland.
Introduction
By reducing the treatment time for patients and health
care professionals as well as the health care costs of
each single therapy, the new application form is
advantageous from a health economic perspective
for the whole society. Yet, the change to the
subcutaneous application results in a decrease in profit
margin for the single drug therapy for both reviewed
health care providers. It might be argued, however,
that health care providers gain time to treat new/other
patients thereby generating additional profit margin.
Conclusion
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The treatment time for the subcutaneous application,
conducted by a nurse, lasts about 15 minutes, whereas
an intravenous administration takes generally about 60
minutes for Herceptin and 90 minutes for MabThera.
Thus, the subcutaneous application results in a time
gain for patients and health care professionals as well
as in an overall cost reduction for all reviewed settings.
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